Roxane Alupent Production To Be Halted While GMP Concerns Are Addressed
• By The Pink Sheet
Roxane Labs is temporarily halting production of its asthma product Alupent following receipt of a July 12 FDA warning letter on GMP deficiencies in the manufacturing of liquid drug products at its Columbus, Ohio facility.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
